On the public citation graph
The anti-inflammatory effects of SGLT inhibitors
0 signed · 41 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1016/j.cjca.2017.07.330openalex-snapshot
DIRECT EFFECTS OF EMPAGLIFLOZIN ON EXTRACELLULAR MATRIX REMODELING IN HUMAN CARDIAC FIBROBLASTS: NOVEL TRANSLATIONAL CLUES TO EMPA-REG OUTCOME
inferredcites →https://doi.org/10.1016/j.freeradbiomed.2017.01.035openalex-snapshot
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
inferredcites →https://doi.org/10.1016/j.jacc.2019.01.056openalex-snapshot
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
inferredcites →https://doi.org/10.1016/j.mce.2019.110487openalex-snapshot
Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice
inferredcites →https://doi.org/10.1080/17425255.2018.1551877openalex-snapshot
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
inferredcites →https://doi.org/10.1080/17425255.2019.1588886openalex-snapshot
Metabolism of the failing heart and the impact of SGLT2 inhibitors
inferredcites →https://doi.org/10.1093/cvr/cvz037openalex-snapshot
Cardiac sodium-dependent glucose cotransporter 1 is a novel mediator of ischaemia/reperfusion injury
inferredcites →https://doi.org/10.22038/ijbms.2019.31788.7651openalex-snapshot
Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis.
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.3897/pharmacia.71.e116184zenodo-depositor-declared
Evaluation of empagliflozin efficacy as a promising anti-aging treatment in mice: In-vivo study
inferred← citeshttps://doi.org/10.1002/jemt.24665openalex-snapshot
Evaluating the potential impact of sodium–glucose cotransporter‐2 inhibitor “canagliflozin” on the hepatic damage triggered by hypertension in rats
inferred← citeshttps://doi.org/10.1007/s00011-023-01796-yopenalex-snapshot
SGLT2 inhibitors prevent LPS-induced M1 macrophage polarization and alleviate inflammatory bowel disease by downregulating NHE1 expression
inferred← citeshttps://doi.org/10.1007/s00210-024-03406-yopenalex-snapshot
The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation
inferred← citeshttps://doi.org/10.1007/s00395-023-01003-3openalex-snapshot
Perspective: mitochondrial STAT3 in cardioprotection
inferred← citeshttps://doi.org/10.1007/s11255-025-04965-6openalex-snapshot
SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients
inferred← citeshttps://doi.org/10.1007/s12035-025-05457-5openalex-snapshot
Targeting Neurodegeneration with SGLT2is: From Molecular Mechanisms to Clinical Implications
inferred← citeshttps://doi.org/10.1007/s12325-023-02652-5openalex-snapshot
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
inferred← citeshttps://doi.org/10.1007/s12672-025-04046-1openalex-snapshot
SGLT2 inhibitors and their role in reducing mortality among cancer patients with type 2 diabetes undergoing immune checkpoint inhibitor therapy
inferred← citeshttps://doi.org/10.1016/j.ahj.2022.01.008openalex-snapshot
Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) – A phase III study
inferred← citeshttps://doi.org/10.1016/j.ajpc.2024.100927openalex-snapshot
Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.jacc.2020.11.008openalex-snapshot
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
inferred← citeshttps://doi.org/10.1055/a-1197-6223openalex-snapshot
Metabolische Wirkungen und kardiovaskuläre Sicherheit einer oralen Dreifachtherapie des Typ-2-Diabetes: das Beispiel Metformin, Empagliflozin und Linagliptin
inferred← citeshttps://doi.org/10.1080/14779072.2020.1802247openalex-snapshot
Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy
inferred← citeshttps://doi.org/10.1080/14779072.2021.1842051openalex-snapshot
Reply: empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention
inferred← citeshttps://doi.org/10.1093/eurheartj/ehac494openalex-snapshot
Empagliflozin in acute myocardial infarction: the EMMY trial
inferred← citeshttps://doi.org/10.1159/000546079openalex-snapshot
SGLT-2 Inhibitors: A Deeper Dive into Their Renal Protective Properties beyond Glycemic Control and Proteinuria Reduction
inferred← citeshttps://doi.org/10.1186/s40959-023-00199-6openalex-snapshot
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.18103/mra.v9i6.2442openalex-snapshot
Empagliflozin, Beyond Glucose Reduction. The Unanticipated and Welcomed Cardioprotective Results. Switching the Heart at Four Levels: Energetic, Anatomical, Functional, and Neuro-Hormonal
inferred← citeshttps://doi.org/10.25122/jml-2023-0343openalex-snapshot
Dapagliflozin mitigates oxidative stress, inflammatory, and histopathological markers of aging in mice
inferred← citeshttps://doi.org/10.3389/fcvm.2022.991716openalex-snapshot
How dysregulation of the immune system promotes diabetes mellitus and cardiovascular risk complications
inferred← citeshttps://doi.org/10.3389/fendo.2026.1776717openalex-snapshot
Sodium-glucose cotransporter-2 inhibitors in cancer patients with type 2 diabetes and established immune checkpoint inhibitor-related cardiotoxicity: a retrospective analysis
inferred← citeshttps://doi.org/10.3390/cancers16071325openalex-snapshot
Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention
inferred← citeshttps://doi.org/10.3390/jcdd10110465openalex-snapshot
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
inferred← citeshttps://doi.org/10.3390/jcm15124681openalex-snapshot
Inflammatory Biomarkers and Their Associations with Arrhythmic Burden Following SGLT2-I Treatment in Chronic Heart Failure—A Subanalysis of the ERASe Trial
inferred← citeshttps://doi.org/10.33963/v.kp.97844openalex-snapshot
Kidneys in heart failure: Impact of flozins
inferred← citeshttps://doi.org/10.34172/npj.12876openalex-snapshot
Reviving the microcirculation; the protective role of SGLT2 inhibitors in counteracting capillary rarefaction
inferred← citeshttps://doi.org/10.4049/immunohorizons.2300077openalex-snapshot
Sodium–Glucose Cotransporter-2 Inhibitor, Empagliflozin, Suppresses the Inflammatory Immune Response to Influenza Infection
inferred← citeshttps://doi.org/10.52711/0974-360x.2022.00747openalex-snapshot
Evaluation of Anti-Inflammatory and Wound Healing Potential of Sodium Glucose Co-Transporter2 (SGLT2) Inhibitors
inferred← citeshttps://doi.org/10.53555/p37cha52openalex-snapshot
EVALUATION OF SAFETY AND EFFICACY OF DAPAGLIFLOZIN AS FIRST LINE MONOTHERAPY WITH METFORMIN IN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS - A RANDOMIZED OPEN LABEL STUDY
inferred← citeshttps://doi.org/10.5397/cise.2024.00969openalex-snapshot
Potentials of SGLT2 inhibitors in the treatment of diabetic rotator cuff diseases: a comprehensive review
inferred← citeshttps://doi.org/10.5551/jat.64395openalex-snapshot
Elevated Leukocyte Count and Platelet-Derived Thrombogenicity Measured Using the Total Thrombus-Formation Analysis System in Patients with ST-Segment Elevation Myocardial Infarction
inferred← citeshttps://doi.org/10.7759/cureus.84768openalex-snapshot
Therapeutic Potential of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Liver Disease: Focus on Cirrhosis
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.